Search

Displaying results 1171 - 1180 of 4539 in total
  1. Drug

    MM-093

    go.drugbank.com/drugs/DB05512
    Investigational

    Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults

  2. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    Dequalinium is an antibacterial agent with multi-targeted actions. It also possesses antifungal, antiparasitic, antiviral, anticancer, and neuroprotective properties. It is a quaternary ammonium compound, as it consists of an amphipathic...

  3. Drug

    Cefamandole

    go.drugbank.com/drugs/DB01326
    ApprovedWithdrawn

    Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.

  4. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain.

  5. Drug

    Gadopentetic acid

    go.drugbank.com/drugs/DB00789
    ApprovedInvestigational

    A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)

  6. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.

  7. Drug

    Padimate A

    go.drugbank.com/drugs/DB11229
    ApprovedWithdrawn

    In Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens.

  8. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to idoxuridine . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epitheli...

  9. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer. … Dendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells.

  10. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.